Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with metastatic melanoma

Next Previous
X
Search
Trial Profile

Phase I study of safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with metastatic melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti GD2 chimeric antigen receptor T cell therapy Bellicum Pharmaceuticals (Primary) ; Vemurafenib
  • Indications Colorectal cancer; Ewing's sarcoma; Fibrosarcoma; Liposarcoma; Malignant melanoma; Osteosarcoma; Rhabdomyosarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Synovial sarcoma; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CARPETS

    • Most Recent Events

    • 23 Sep 2023 Primary endpoint (The feasibility of preparing T cell products for administration to patients receiving vemurafenib will be determined as the frequency of successfully administered products. Acceptable feasibility is defined as the administration to patients of or equal to 75% of prepared T cells products.) has been met according to result presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
    • 23 Sep 2023 Status changed from not yet recruiting to active, no longer recruiting according to result presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
    • 23 Sep 2023 Results presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top